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A B S T R A CT  
COVID-19 a global pandemic is a cause for panic due to the increasing numbers and the 
associated fatality rate of ~5%. Death due to COVID-19 is ascribed majorly to the cytokine 
storm a hyper immune reaction that results in acute respiratory distress syndrome. 
Following the WHO Solidarity initiative, a large number of clinical trials approved at 
breakneck speed across the globe. It is encouraging to note that almost all trials are 
addressing both antiviral effect and lung protection. Clinical trials with a focus on decreasing 
mortality indeed harbinger a positive trend, as the world waits expectantly for a solution to 
this dreaded COVID-19 pandemic. 
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1 Introduction 
The Novel Coronavirus Disease 2019 (COVID-19), a global pandemic has brought the world to a 
grinding halt. Statistics are grim with over 10.9 million infected with SARS-CoV-2, numbers steadily rising 
and over 0.5 million deaths worldwide (~5% death rate) [1]. Lockdown would enable flattening the curve, 
but remain a will-o'-the-wisp if the fatality is not controlled [2]. The continuous research suggests the 
demand for clarity on COVID-19 pathophysiology, which is crucial for successful therapeutic 
interventions [3].  
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Most COVID-19 fatalities are attributed to respiratory failure triggered by a hyper-immune response 
called the "Cytokine storm" [4, 5]. They usually are turned on briefly and switch off automatically. 
However, under a highly virulent attack as in COVID-19, the storm characterized by an upsurge of 
proinflammatory cytokines, interleukins (IL-1, IL-6), chemokines (CCR5), colony-stimulating factors 
(GM-CSF), interferons (Type I IFN) and tumour necrosis factor (TNF-α) becomes unstoppable. The 
result is acute respiratory distress syndrome (ARDS), and acute cardiac injury, related mortality. This 
condition may further be complicated by severe pneumonia, to enhance mortality [6–9]. In COVID-19 
patients, this storm generally occurs during the second week as a sudden and unexpected onslaught and 
patients rapidly worsen. Within 24 hours, patients may need to be switched from oxygen to ventilators [3, 
10]. Although SARS-CoV-2 induced pneumonia is marked by a production of the inflammatory cytokine 
IL-6, other cytokines like IL-1 and TNF-α, which are produced could worsen the condition and culminate 
in a fatal outcome as seen in patients of COVID-19 [10, 11]. Several clinical trials have approved at 
unimaginable speeds and are mainly based on drug repurposing approach [12, 13]. Notably, the 
pathogenesis of cytokine storm is complex and can be exacerbated in comorbidities, leading to death [14]. 
Similarly, this cytokine response is not the same in the context of all infections, and the situation gets 
even more complicated in patients living with coinfections [15]. Translating any drugs from past and 
based on addressing one immunopathology into COVID-19 associated Immune storm which involves 
many such pathways and many unknown mechanisms are challenging in critically ill patients, and side 
effects may increase mortality [4, 7, 9]. 
The WHO Solidarity Trial approved in March, which included Remdesivir, Lopinavir/Ritonavir, 
Lopinavir/Ritonavir with Interferon β-1a, and the antimalarials Chloroquine/ Hydroxychloroquine 
focused primarily on antiviral activity. However, combining the anti-inflammatory cytokine interferon 
with the antivirals, as an inhalation, reflects that lung protection was a considered factor [16]. 
Hydroxychloroquine (HCQ) is reported to prevent viral multiplication and also inhibit IL-6. 
Nevertheless, the results of the WHO solidarity trial were not astounding or robust. Convalescent plasma 
therapy could only provide a stopgap during the pandemic, and vaccines need time for development [17, 
18].  There is an urgent need, therefore for drugs/drug combinations that exhibit not only the high 
antiviral activity but also protect the lungs, to limit the mortality rate[3, 10]. In the light of such a need, 
this review highlights the approved clinical trials to understand the trend towards addressing the immune 
storm. 
2 COVID-19 Immune Storm Pathogenesis 
One study confirmed that SARS-CoV-2 could escape the IFN-I response [19]. Similar to SARS-CoV, it 
can block host innate immune responses and thus disturbs the host antiviral defence mechanism [20, 21]. 
It also causes T cell exhaustion and accumulation of lymphocytes in the lungs, which causes lung injury 
[22–25]. SARS-CoV-2 enters inside the cell through angiotensin-converting enzyme-2 (ACE2) receptors 
[26]. The viral entry causes downregulation of ACE2 receptor, which ultimately disturbs the renin-
angiotensin pathway and causes angiotensin II generation. This angiotensin II then causes vascular 
damage, cell damage, inflammation and leads to acute respiratory distress syndrome (ARDS) [3, 27, 28]. 
The viral genome inside cell activates various proinflammatory signalling pathways, which causes 
continuous upsurge of several cytokines leading towards Cytokine Storm. This storm constitutes high 
systemic levels of Interleukins (IL-1, IL-2, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-17, IL-18), Interferons 
(IFN), Interferon Inducible protein (IP-10), Tumour necrosis factor (TNF-α), growth factors, Colony-
stimulating factors, macrophage inflammatory protein (MIP1), monocyte chemoattractant protein (MCP), 
and Chemokines[6–9]. 
3 Clinical Trials Addressing COVID-19 Immune Storm 
In this section, the summary of molecules considered for COVID-19 clinical trials is discussed (Fig 1) 
[Clinical Trial Search: www.clinicaltrials.gov ] 
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Figure 1: COVID-19 Clinical Trials Addressing Immune Storm 
 
3.1 Anti-cytokine Therapeutics 
The first randomized trial of Baricitinib (Olumiant®) identified as a potential antiviral with anti-cytokine 
properties, for COVID-19 in April, is an essential step in this direction. Ruxolitinib (Jakafi®) is an IL-6 
inhibitor, while Acalabrutinib (Calquence®) is an IL-1 and IL-6 inhibitor [29]. Monoclonal antibodies 
(MAbs) which could provide such dual action are also under investigation. Tocilizumab (Actemra®) an 
IL-6, Janus kinase (JAK) and TNF inhibitor, which could curb inflammation and inhibit intracellular viral 
entry of SARS-CoV-2, has shown promise in patients with a so-called cytokine storm. The trial is 
approved in China for patients with elevated IL-6 and COVID-19 pneumonia [30]. Anti-CD147 
humanized Meplazumab can target the virus and also prevent lung damage. It is known to block the 
invasion of host cells by SARS-CoV-2. A trial in China has revealed promise [31]. Other MAbs in clinical 
trials focus on protecting the lungs of severely ill patients by different mechanisms, on decreasing 
mortality. Siltuximab (Sylvant®), Clazakizumab, Sarilumab (Kevzara®) are IL-6 inhibitors [32], 
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Anakinra® and Canakinumab (Ilaris®) are IL-1 inhibitors [33], Adalimumab (Humira®) is a TNF 
inhibitor [34], while Emapalumab (Gamifant®) is a IFN gamma inhibitor [35].  GM-CSF inhibitors 
include Mavrilimumab, TJ003234, and Lenzilumab (Humaneered®) [36], while Leronlimab (PRO 140) is 
CCR5 antagonist [37]. Eculizumab (Soliris®) is reported to modulate the complement activity. Thus 
could help halt mortality, thereby providing the patient time to recover with supportive medical care [38]. 
Bevacizumab (Avastin®), an anti-VEGF drug, could facilitate suppression of pulmonary edema, and is 
being investigated for ALI/ARDS in COVID-19 [39].  
3.2 Mesenchymal Stem Cells Therapy 
Based on their anti-inflammatory and immunomodulatory properties in pulmonary diseases, 
Mesenchymal Stem cells, are being tested in several COVID-19 clinical trials [40]. Along with 
immunomodulatory activity, they can reclaim the pulmonary microenvironment, protect alveolar 
epithelial cells, avert pulmonary fibrosis, and cure lung dysfunction. However, significant challenges are 
associated with bringing stem cell therapy to the clinic [41, 42].  
3.3 Immunomodulatory Agents 
A number of immunomodulatory drugs are also enlisted in clinical trials against COVID-19 [39].  
Thalidomide increases the secretion of anti-inflammatory interleukins, such as IL-12, activates natural 
killer cells, and alleviates TNFα to control lung inflammation in severe pneumonia [43]. Yet another 
immunomodulatory agent Fingolimod (FTY720) a sphingosine-1-phosphate receptor regulator is 
repositioned for COVID-19 to address the cytokine storm [44]. Sargramostim (Leukine®) the only FDA 
approved recombinant humanized granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) can 
augment innate host defence and lungs health, and possibly reduce risk of secondary infections. Leukine® 
showed beneficial effects in patients with viral pneumonia [45]. Other drugs that can address hyper 
inflammation include OX40-Ig fusion proteins, PUL042 a Toll-like receptor agonist, Piclidenoson and 
Sildenafil (Viagra®), and Nitric oxide inhalation therapy [46, 47].  CD24Fc, a biological 
immunomodulatory agent, curbing the production of multiple inflammatory cytokines has entered phase 
III clinical trials against COVID-19 [48].  
3.4 Combination of Antiviral and Anticytokine Therapeutics 
The antiprotozoal Nitazoxanide [49] and anthelmintic Ivermectin [50] which demonstrated in vitro 
antiviral efficacy against SARS-CoV-2, are recently enrolled in the COVID-19 fight. Both drugs can 
inhibit the cytokine storm, and not just IL-6 but also other pro-inflammatory cytokines. Efforts to 
address the cytokine storm are evident in clinical trials which combine antivirals with drugs that can 
alleviate the inmmune storm as seen with Tocilizumab/HCQ/Azithromycin (NCT04332094; Spain), 
Remdesivir/HCQ (NCT04321616; Norway), Baricitinib/HCQ (NCT04373044; USA), 
Favipiravir/Tocilizumab (NCT04310228; China), and Favipiravir/Oseltamivir/HCQ (NCT04303299; 
Thailand) [51]. 
Clinicians are already treating patients with powerful anti-inflammatory drugs like steroids 
(methylprednisolone, dexamethasone), COX inhibitors (mesalamine, celecoxib), and seeing symptomatic 
relief [52]. However, corticosteroids might aggravate COVID-19 related lung injury and must be used 
with caution, immunosuppression may not always be beneficial in hyperinflammation, and may be 
contraindicated [53]. Since it is observed that the cytokine storm generally occurs in the second week of 
the infection, perhaps screening patients with severe COVID-19 for hyper inflammation using simple 
laboratory tests like decreasing platelet counts, increasing ferritin, or erythrocyte sedimentation rate at an 
appropriate time could provide an opportunity to thwart the immune storm [11, 54]. 
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4 Conclusion 
Clinical trials with a focus on decreasing mortality indeed harbinger a positive trend, as the world waits 
expectantly for a solution to this dreaded COVID-19 pandemic. Attempts need to be focused on 
Combination therapeutics to control the overall storm with rapid viral clearance and reduce severe side 
effects. Promising COVID-19 therapy is still awaiting. 
5 Competing Interests 




[1] “WHO,” WHO Coronavirus Disease (COVID-19) Dashboard, Jun. 30, 2020. 
https://covid19.who.int/?gclid=EAIaIQobChMIleGg_tKp6gIVCB4rCh26ggk4EAAYASAAEgKEhvD_BwE (accessed Jun. 08, 
2020). 
[2] J. Amir Singh, “COVID-19: Science and global health governance under attack,” SAMJ: South African Medical Journal, vol. 110, 
no. 6, pp. 1–2, 2020. 
[3] Y. Jamilloux et al., “Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions,” 
Autoimmunity Reviews, p. 102567, 2020. 
[4] X. Cao, “COVID-19: immunopathology and its implications for therapy,” Nature Reviews Immunology, vol. 20, no. 5, Art. no. 5, 
May 2020, doi: 10.1038/s41577-020-0308-3. 
[5] R. J. Jose and A. Manuel, “COVID-19 cytokine storm: the interplay between inflammation and coagulation,” The Lancet 
Respiratory Medicine, vol. 8, no. 6, pp. e46–e47, Jun. 2020, doi: 10.1016/S2213-2600(20)30216-2. 
[6] V. J. Costela-Ruiz, R. Illescas-Montes, J. M. Puerta-Puerta, C. Ruiz, and L. Melguizo-Rodríguez, “SARS-CoV-2 infection: The role 
of cytokines in COVID-19 disease,” Cytokine Growth Factor Rev, Jun. 2020, doi: 10.1016/j.cytogfr.2020.06.001. 
[7] L. A. Henderson et al., “On the alert for cytokine storm: Immunopathology in COVID-19,” Arthritis & Rheumatology, 2020. 
[8] N. Mangalmurti and C. A. Hunter, “Cytokine Storms: Understanding COVID-19,” Immunity, 2020. 
[9] N. Vabret et al., “Immunology of COVID-19: Current State of the Science,” Immunity, vol. 52, no. 6, pp. 910–941, Jun. 2020, doi: 
10.1016/j.immuni.2020.05.002. 
[10] S. H. Nile, A. Nile, J. Qiu, L. Li, X. Jia, and G. Kai, “COVID-19: Pathogenesis, cytokine storm and therapeutic potential of 
interferons,” Cytokine & Growth Factor Reviews, 2020. 
[11] F. Zeng, Y. Guo, M. Yin, X. Chen, and G. Deng, “Association of inflammatory markers with the severity of COVID-19,” medRxiv, 
2020. 
[12] R. K. Guy, R. S. DiPaola, F. Romanelli, and R. E. Dutch, “Rapid repurposing of drugs for COVID-19,” Science, vol. 368, no. 6493, 
pp. 829–830, 2020. 
[13] S. L. Senanayake, Drug repurposing strategies for COVID-19. Future Science, 2020. 
[14] C. Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The lancet, vol. 395, no. 
10223, pp. 497–506, 2020. 
[15] T. M. C. de Lucena, A. F. da Silva Santos, B. R. de Lima Fabrício, M. E. de Albuquerque Borborema, and J. de Azevêdo Silva, 
“Mechanism of inflammatory response in associated comorbidities in COVID-19,” Diabetes & Metabolic Syndrome: Clinical 
Research & Reviews, 2020. 
[16] K. Kupferschmidt and J. Cohen, Race to find COVID-19 treatments accelerates. American Association for the Advancement of 
Science, 2020. 
[17] Z. Jin, J.-Y. Liu, R. Feng, L. Ji, Z.-L. Jin, and H.-B. Li, “Drug treatment of coronavirus disease 2019 (COVID-19) in China.,” 
European Journal of Pharmacology, p. 173326, Jun. 2020, doi: 10.1016/j.ejphar.2020.173326. 
[18] U. Sandkovsky, P. Colley, T. Sam, A. M. Modrykamien, and M. Berhe, “The dynamic treatment of SARS-CoV-2 disease,” Baylor 
University Medical Center Proceedings, pp. 1–8, Jun. 2020, doi: 10.1080/08998280.2020.1780086. 
[19] J. Hadjadj et al., “Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients,” 
MedRxiv, 2020. 
[20] D. E. Gordon et al., “A SARS-CoV-2 protein interaction map reveals targets for drug repurposing,” Nature, pp. 1–13, 2020. 
[21] J. Rehwinkel and M. U. Gack, “RIG-I-like receptors: their regulation and roles in RNA sensing,” Nature Reviews Immunology, pp. 
1–15, 2020. 
[22] B. Diao et al., “Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19),” Frontiers in 
Immunology, vol. 11, p. 827, 2020. 
[23] C. Moon, Fighting COVID-19 exhausts T cells. Nature Publishing Group, 2020. 
[24] F. Venet, C.-S. Chung, X. Huang, J. Lomas-Neira, Y. Chen, and A. Ayala, “Lymphocytes in the Development of Lung 
Inflammation: A Role for Regulatory CD4+ T Cells in Indirect Pulmonary Lung Injury,” J Immunol, vol. 183, no. 5, pp. 3472–3480, 
Sep. 2009, doi: 10.4049/jimmunol.0804119. 
[25] K. Yuki, M. Fujiogi, and S. Koutsogiannaki, “COVID-19 pathophysiology: A review,” Clin Immunol, vol. 215, p. 108427, Jun. 
2020, doi: 10.1016/j.clim.2020.108427. 
[26] H. Zhang, J. M. Penninger, Y. Li, N. Zhong, and A. S. Slutsky, “Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 
receptor: molecular mechanisms and potential therapeutic target,” Intensive care medicine, vol. 46, no. 4, pp. 586–590, 2020. 
Addressing COVID-19 Immune Storm: A Way Forward 
Page 6 of 6 
 
AIJR Preprints 
Available online at preprints.aijr.org 
[27] M. Hoffmann et al., “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease 
inhibitor,” Cell, 2020. 
[28] L. Samavati and B. D. Uhal, “ACE2, Much More Than Just a Receptor for SARS-COV-2,” Frontiers in Cellular and Infection 
Microbiology, vol. 10, p. 317, 2020. 
[29] M. Benucci, A. Damiani, M. Infantino, M. Manfredi, and L. Quartuccio, “Old and new antirheumatic drugs for the treatment of 
COVID-19,” Joint Bone Spine, vol. 87, no. 3, p. 195, 2020. 
[30] X. Xu et al., “Effective treatment of severe COVID-19 patients with tocilizumab,” Proceedings of the National Academy of 
Sciences, vol. 117, no. 20, pp. 10970–10975, 2020. 
[31] H. Bian et al., “Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial,” MedRxiv, 
2020. 
[32] B. Liu, M. Li, Z. Zhou, X. Guan, and Y. Xiang, “Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-
19)-induced cytokine release syndrome (CRS)?” Journal of Autoimmunity, p. 102452, 2020. 
[33] B. Russell et al., “Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of 
current evidence,” ecancermedicalscience, vol. 14, 2020. 
[34] G. Monteleone, P. C. Sarzi-Puttini, and S. Ardizzone, “Preventing COVID-19-induced pneumonia with anticytokine therapy,” The 
Lancet Rheumatology, vol. 2, no. 5, pp. e255–e256, 2020. 
[35] G. Giovannoni, “Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19,” Multiple Sclerosis and Related 
Disorders, 2020. 
[36] E. G. Favalli and R. Caporali, “GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?” 
The Lancet Rheumatology, 2020. 
[37] T. P. Velavan and C. G. Meyer, “The COVID-19 epidemic,” Tropical medicine & international health, vol. 25, no. 3, p. 278, 2020. 
[38] F. Diurno et al., “Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord 
experience.,” European review for medical and pharmacological sciences, vol. 24, no. 7, pp. 4040–4047, 2020. 
[39] S. G. V. Rosa and W. C. Santos, “Clinical trials on drug repositioning for COVID-19 treatment,” Revista Panamericana de Salud 
Pública, vol. 44, p. e40, 2020. 
[40] A. Golchin, E. Seyedjafari, and A. Ardeshirylajimi, “Mesenchymal stem cell therapy for COVID-19: present or future,” Stem cell 
reviews and reports, pp. 1–7, 2020. 
[41] P. P. Roudsari et al., “Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory 
processes of severe acute respiratory infections caused by COVID-19,” Cell and Tissue Banking, pp. 1–21, 2020. 
[42] B. Chitra, P. S. Surinder, and C. Sangeeta, “Can Mesenchymal Stem Cell Therapy Be the Interim Management of COVID-19?” 
Drug discoveries & therapeutics. 
[43] F. Dastan et al., “Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces,” Iranian 
Journal of Pharmaceutical Research, vol. 19, no. 1, pp. 1–2, 2020. 
[44] K.-H. Chen et al., “Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019,” 
Journal of the Chinese Medical Association, 2020. 
[45] C. Bosteels et al., “Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured 
summary of a study protocol for a randomised controlled trial,” Trials, vol. 21, no. 1, pp. 1–2, 2020. 
[46] F. J. R. Paumgartten, I. F. Delgado, L. da Rocha Pitta, and A. C. A. X. de Oliveira, “Drug repurposing clinical trials in the search for 
life-saving Covid-19 therapies; research targets and methodological and ethical issues,” Vigilância Sanitária em Debate: Sociedade, 
Ciência & Tecnologia, 2020. 
[47] A. Pandey et al., “Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent 
advancements,” Life Sciences, p. 117883, 2020. 
[48] R.-R. Tian et al., “CD24Fc protects against viral pneumonia in simian immunodeficiency virus-infected Chinese rhesus monkeys,” 
Cellular & Molecular Immunology, pp. 1–2, 2020. 
[49] P. R. Martins-Filho, J. A. Barreto-Alves, and R. Fakhouri, “Potential role for nitazoxanide in treating SARS-CoV-2 infection,” 
American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 319, no. 1, pp. L35–L36, 2020. 
[50] D. Gupta, A. K. Sahoo, and A. Singh, “Ivermectin: potential candidate for the treatment of COVID-19,” The Brazilian Journal of 
Infectious Diseases, 2020. 
[51] N. Hossein-khannazer, B. Shokoohian, A. Shpichka, H. A. Aghdaei, P. Timashev, and M. Vosough, “Novel therapeutic approaches 
for treatment of COVID-19,” Journal of Molecular Medicine (Berlin, Germany), p. 1, 2020. 
[52] B. Russell, C. Moss, A. Rigg, and M. Van Hemelrijck, “COVID-19 and treatment with NSAIDs and corticosteroids: should we be 
limiting their use in the clinical setting?” ecancermedicalscience, vol. 14, 2020. 
[53] L. Zha et al., “Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19),” Medical Journal of Australia, vol. 
212, no. 9, pp. 416–420, 2020. 
[54] M. Kermali, R. K. Khalsa, K. Pillai, Z. Ismail, and A. Harky, “The role of biomarkers in diagnosis of COVID-19–A systematic 
review,” Life Sciences, p. 117788, 2020. 
 
